Fungal β-1,3-glucans: cell wall constituents modulating innate gut immunity
This narrative review describes mechanisms by which fungal β-1,3-glucans interact with intestinal immune receptors but provides no clinical efficacy data in humans to support therapeutic recommendations.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Dectin-1 activation and NF-κB signaling | D | ▲ Favorable | descritivo; sem tamanho de efeito quantificado | — |
| Gut microbiota modulation (Lactobacillus/Bifidobacterium) | D | ▲ Favorable | descritivo; dados preclinicos; sem IC 95% | — |
| Intestinal barrier integrity | D | — Insufficient | sem dados quantitativos reportados | — |
| CR3/NK-mediated antitumor cytotoxicity | D | ▲ Favorable | descritivo; modelos in vitro e murinos; sem IC 95% | — |
| SCFA production via colonic fermentation | D | — Insufficient | descritivo; sem magnitude quantificada em humanos | — |
| Clinical outcomes in inflammatory bowel disease | D | — Insufficient | nao avaliado com RCTs nesta revisao | — |
| Efficacy as adjuvant in cancer immunotherapy | D | — Insufficient | citados estudos clinicos selecionados sem pooling; sem IC 95% | — |
Context
β-1,3-glucans constitute 30–80% of the fungal cell wall and are absent in mammals, making them immunologically distinct targets. They interact with Dectin-1, TLRs, CR3, and other pattern recognition receptors in gut-associated lymphoid tissue. Whether dietary intake of these molecules produces measurable clinical benefits remains unanswered by robust evidence.
What the study showed
The review compiles mechanistic evidence that fungal β-1,3-glucans activate Dectin-1, TLR2/TLR4, CR3, and LacCer on macrophages, neutrophils, and dendritic cells, triggering NF-κB, CARD9-Bcl10-Malt1, and MAP kinase pathways. Preclinical data indicate promotion of Lactobacillus and Bifidobacterium and suppression of opportunistic pathogens. No randomized clinical trial data with validated primary endpoints are presented with absolute numbers or confidence intervals. The direction of immunological effects is considered favorable in the reviewed models, but clinical magnitude in humans is not quantified.
How it was done
Narrative review published in Nutrients (2026); no registered protocol, no reported systematic search strategy, no explicit inclusion/exclusion criteria. Synthesizes mechanistic literature, in vitro studies, animal models, and selected clinical trials without meta-analysis. Aggregate sample size is not applicable.
Effect magnitude
No consolidated effect size with 95% CI is reported. Individual effects cited are extracted from heterogeneous studies without statistical pooling.
Limitations
Narrative review with no formal risk-of-bias assessment (AMSTAR-2, RoB 2, or ROBINS-I tools were not applied). Absence of systematic selection criteria introduces publication bias and confirmation bias. Most evidence is preclinical (in vitro or murine models), and direct extrapolation to humans is not justified by the presented data. Heterogeneity in fungal sources, doses, administration routes, and studied populations precludes unified clinical conclusions.
In clinical practice
Clinicians should not change practice based on this review alone. Fungal β-1,3-glucans have an acceptable safety profile as a food component, but clinical efficacy in specific conditions requires confirmation by RCTs with validated endpoints. Monitoring of immunocompromised patients is prudent given the potential for inflammatory modulation.
What is still missing
RCTs in humans with clinical primary endpoints (infection recurrence, validated inflammatory markers, measurable intestinal permeability) and standardized doses of fungal β-1,3-glucans are needed. Shotgun-sequencing microbiota studies linked to immunological outcomes in specific populations (IBD, oncology, immunocompromised) are the next research priority.